Health-care companies claim they are not threatened by Amazon's potential foray into the space. A recent lawsuit suggests otherwise.Technologyread more
It wasn't supposed to be this way: The 2017 tax cut and aggressive moves toward deregulation were supposed to pull the U.S. economy out of its glacial move higher.Economyread more
The yield on the benchmark 10-year Treasury note fell below 2% for the first time since November 2016 on Wednesday.Bondsread more
Slack pursued an unusual direct listing, meaning it did not have banks underwrite the offering.CNBC Disruptor 50read more
President Trump says Iran may not have intentionally downed an unmanned U.S. surveillance drone.Politicsread more
Slack's public market debut on Thursday will generate billions for venture firm Accel and healthy returns for Andreessen Horowitz and Social Capital.Technologyread more
The road to the Fed's policy pivot to lower interest rates began in early May, with a tweet from President Trump on trade.Market Insiderread more
See which stocks are posting big moves after the bell on June 20.Market Insiderread more
Chairman Jerry Nadler, D-N.Y., said in a statement that lawyers for the Trump administration blocked Hicks from answering questions 155 times during the Wednesday hearing.Politicsread more
Jim Cramer says "you'll want to keep some powder dry so you can buy into weakness and get some real bargains."Mad Money with Jim Cramerread more
CNBC analysis using Kensho found that Disney, Verizon and Home Depot were some of the best performing Dow stocks in declining-rate environments.Investingread more
"We can see the opportunity for cures [for cancer] in a relatively short time frame."
That's what Dr. Gary Gilliland, President and Director of the Fred Hutchinson Cancer Research Center in Seattle, said in a Power Lunch interview.
Dr. Gilliland's optimism comes from the development of CAR-T(chimeric antigen receptor T) cells which can be genetically engineered to "seek and destroy cancer cells."
Dr. Gilliland says he has seen "tumors melt away" in patients for whom no other treatment has been effective.
Juno Therapeutics is one of the leading companies working on this form of cancer treatment. Juno was started as a collaboration between scientists at Fred Hutchinson, Memorial Sloan-Kettering Cancer Center in New York and Seattle Children's Research Institute.
Dr. Gilliland says the best data for this treatment exists for blood-borne cancers like leukemia, but he is hopeful it could be expanded to treat more common forms of cancer like breast cancer and lung cancer.
"We're not looking to treat cancers at the Hutch, we're looking to cure cancers. And we do see that opportunity coming."